Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial.

Samankaltaisia teoksia

• Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial.
  Tekijä: De Rossi, A, et al.
  Julkaistu: (2002)
• Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
  Tekijä: Gibb, D, et al.
  Julkaistu: (2002)
• Identification of the phenotypic, genotypic and fitness correlates of non-B subtype HIV-1 NRTI resistance through longitudinal analysis of children with virological failure in the developing world
  Tekijä: Mbisa, J, et al.
  Julkaistu: (2010)
• Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets
  Tekijä: Bienczak, A, et al.
  Julkaistu: (2017)
• Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
  Tekijä: Shafer, R, et al.
  Julkaistu: (1995)